Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
- Astellas to Discontinue IBS Med Colonel in Product Consolidation
January 24, 2024
- Astellas to Transfer Distribution Rights for Antibacterial Geninax to Taisho
January 24, 2024
- Mitsubishi Tanabe, Pfizer to Copromote 5-in-1 Vaccine Gobik
January 24, 2024
- Prefilled Syringe Versions of Hizentra Approved in Japan: CSL
January 23, 2024
- Nippon Shinyaku Snags EU Orphan Tag for EGPA Drug
January 23, 2024
- Moderna Japan Files 0.5 mL Vial Formulation for Spikevax
January 22, 2024
- Employee Sues Alexion for Sidelining in Reprisal against Whistleblowing
January 19, 2024
- Daiichi, Mitsubishi Curb MR Vaccine Shipments in Response to Takeda’s Recall
January 19, 2024
- LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
- Parmodia Tops November GP Rep Promotion List, Dayvigo HP Champion for 4th Month
January 18, 2024
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- Taisho Set for Delisting as Early as April after Tender Offer Completed
January 17, 2024
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…